Form 4: OrbiMed Increases Stake in ImageneBio via Private Placement

OrbiMed Advisors acquired 721,292 pre-funded warrants in a private placement transaction with ImageneBio, Inc.

Summary

• OrbiMed Advisors LLC and its affiliates acquired 721,292 pre-funded warrants to purchase common stock of ImageneBio, Inc.
• The transaction closed on April 14, 2026, following a securities purchase agreement dated April 12, 2026.
• The purchase price for the pre-funded warrants was $5.199 per warrant.
• The warrants are exercisable at any time with an exercise price of $0.001 per share, subject to a 19.99% beneficial ownership blocker.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive development, as it indicates continued financial backing from a key institutional investor, though it introduces potential dilution.

Positives

• Demonstrates continued institutional support and capital commitment from a major shareholder (OrbiMed).
• Strengthens the company's balance sheet through a private placement capital raise.

Negatives

• The issuance of additional warrants results in potential future dilution for existing shareholders upon exercise.

Risks

• Beneficial ownership blocker of 19.99% limits the immediate exercise capacity of the reporting persons.
• Market volatility could impact the value of the underlying common stock.

Future Outlook

The warrants are exercisable at any time after issuance, providing the holders with the ability to increase their equity stake in ImageneBio at their discretion, subject to ownership limitations.

Management Comments

• The reporting persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
• David P. Bonita serves as the designated representative of OrbiMed Advisors on the Issuer's board of directors.

Industry Context

StockSavvy.ai notes that private placements involving major institutional investors like OrbiMed are common in the biotech sector to ensure runway for clinical development or operational milestones without the volatility of a public offering.

Comparison to Industry Standards

• The use of pre-funded warrants is a standard mechanism in biotech financing to allow investors to hold equity-like instruments while managing regulatory ownership thresholds.
• The 19.99% ownership blocker is a standard provision in private placements to avoid triggering certain exchange-related shareholder approval requirements.

Related Party Transactions

• The transaction involves OrbiMed Advisors, which holds a board seat on the Issuer through David P. Bonita.

Stakeholder Impact

• Shareholders may experience dilution upon the exercise of the warrants.
• The company gains capital to support its operations.

Next Steps

• Potential future exercise of pre-funded warrants by OrbiMed entities.
• Ongoing board representation by David P. Bonita.

Key Dates

Keywords

ImageneBio, OrbiMed, Private Placement, Form 4, Pre-funded Warrants, Insider Ownership